P-Selectin Glycoprotein Ligand-1/CD162 Extracellular Domain (human, recombinant; His-tagged)

P-selectin glycoprotein ligand 1 (PSGL-1), also known as CD162, is a cell surface glycoprotein encoded by SELPLG in humans that binds to P-, E-, and L-selectins to mediate the rolling and tethering of immune cells on endothelium for migration into sites of inflammation.^1,2,3 It is expressed as a homodimer on myeloid and lymphoid cells, including platelets, and is composed of an extracellular domain, which contains branching sites for glycosylation and sulfation, a transmembrane domain, and a cytoplasmic domain.² PSGL-1 selectin binding requires post-translational modifications, including sulfation and glycosylation, and these modifications are constitutively present on PSGL-1 in innate immune cells and differentiated T cells.⁴ Ectopic expression of PSGL-1 in CD4⁺ T cells inhibits processing and incorporation of the HIV-1 envelope glycoprotein, disrupting attachment of viral progeny to target cells but does not inhibit HIV-1 infection.⁵ It also inhibits the incorporation of severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 spike glycoproteins into pseudovirions and blocks pseudovirus attachment and infection of target cells.³ Cayman’s PSGL-1 (human, recombinant; His-tagged) protein consists of 289 amino acids, has a calculated molecular weight of 30.5 kDa, and a predicted N-terminus of Leu18 after signal peptide cleavage. By SDS-PAGE, under reducing conditions, the apparent molecular mass of the protein is approximately 89 or 61 kDa due to glycosylation.

WARNING This product is not for human or veterinary use.

1. Carlow, D.A., Gossens, K., Naus, S., et al. PSGL-1 function in immunity and steady state homeostasis. Immunol. Rev. 230(1), 75-96 (2009).

2. Tinoco, R., Otero, D.C., Takahashi, A.A., et al. PSGL-1: A new player in the immune checkpoint landscape. Trends Immunol. 38(5), 323-335 (2017).

3. He, S., Waheed, A.A., Hetrick, B., et al. PSGL-1 inhibits the incorporation of SARS-CoV and SARS-CoV-2 spike glycoproteins into pseudovirions and impairs pseudovirus attachment and infectivity. Viruses 13(1), 46 (2020).

4. Tinoco, R., Neubert, E.N., Stairiker, C.J., et al. PSGL-1 is a T cell intrinsic inhibitor that regulates effector and memory differentiation and responses during viral infection. Front. Immunol. 12, 677824 (2021).

5. Fu, Y., He, S., Waheed, A.A., et al. PSGL-1 restricts HIV-1 infectivity by blocking virus particle attachment to target cells. Proc. Natl. Acad. Sci. USA 117(17), 9537-9545 (2020).